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Antifungal prophylaxis with posaconazole (POS) has been shown to decrease the mortality associated 
with invasive fungal infections in high-risk patients.We report on a patient, with severe graft-versus-
host disease after allogeneic stem cell transplantation, who developed proven pneumonia due to 
Rhizopus microsporus after 40 days of POS prophylaxis (fasting serum levels: 691^904 ng/mL). 
Despite combination treatment with liposomal amphotericin B and POS for 39 days, the patient died 
from pulmonary hemorrhage.This case highlights the need for continued awareness of breakthrough 
zygomycosis in patients receiving POS. 
 
 
Invasive fungal infections remain a major complication in patients with graft-versus-host disease 
(GVHD) after allogeneic stem cell transplantation. The administration of posaconazole (POS) has 
been shown to reduce the mortality attributable to invasive fungal infections in these highrisk 
patients (1).Very few breakthrough infections, mainly due to Aspergillus and Candida species, have 
been described in the initial trial (1). So far only 1 case of breakthrough infection due to Zygomycetes 





In August 2007, a 60-year-old male patient received an allogeneic stem cell graft for acute 
myelogenous leukemia. He had no history of a prior invasive fungal infection and there were no major 
infectious complications before engraftment. The patient was readmitted on day 95 after 
transplantation because of intestinal GVHD (grade III). He was treated with prednisolone, 
mycophenolate mofetil, pentostatin, and cyclosporin A (which was later switched to tacrolimus). This 
treatment resulted in improvement of the symptoms of GVHD but was complicated by steroidinduced 
diabetes mellitus (without lactic acidosis) and worsening of a preexisting chronic renal insu⁄ciency. At 
the time of diagnosis of GVHD, the patient complained about a dry cough, and a computed 
tomography (CT) scan of the chest was performed. It showed a lesion with a peripheral halo in the 
anterior segment of the right upper lobe suggestive of an invasive mold infection. Because of the 
reduced general condition of the patient, he was treated with voriconazole (intravenous, then oral) 
without further invasive diagnostics for microbiological confirmation of the suspected invasive 
aspergillosis.The dry cough completely resolved and a follow-up CT scan on day 1164 showed 
residual scarring of the lesion.Voriconazole treatment was stopped on day 1188 after transplantation 
and POS (200mg 3 times a day) was started as secondary prophylaxis.The patient was discharged 
with stable symptoms of GVHD on continued immunosuppressive treatment. Despite persistent 
diarrhea, tacrolimus blood levels indicated adequate resorption of oral drugs. POS trough levels, 
determined by a high-performance liquid chromatographic assay performed on stored frozen fasting 
blood samples obtained on days 25 and 35 of POS prophylaxis, were 691 and 904 ng/mL. 
 
On day 40 of POS prophylaxis, the patient was readmitted with worsening fatigue, a dry cough, and 
elevated Creactive protein (41mg/L; normalo5mg/L).The blood cell count showed pancytopenia 
(leukocytes 1.4 x 109/L, haemoglobin 5.9 g/dL, and platelets 20 x 109/L) probably due to valganciclovir 
treatment for cytomegalovirus reactivation. A relapse of leukemiawas thought to be unlikely because 
of donor chimerism of 100% in the peripheral blood. A CT scan of the chest showed a new mass 
lesion in the posterior segment of the right upper lobe (Fig. 1a).The scar in the anterior segment of the 
  
right upper lobe was unchanged. POS was stopped, and caspofungin and broad-spectrum 
antibacterials were initiated.  
 
On day 5 after admission, bronchoscopy revealed a necrotic mucosal lesion of the corresponding 
bronchus. Histology from that lesion revealed broad, unseptated hyphae suggestive for zygomycosis. 
Antifungal therapy was changed to liposomal amphotericin B (AmB) (3mg/ kg) on day 6. A zygomycete 
was cultured from bronchoalveolar lavage, phenotypically identified as Rhizopus microsporus. This 
was confirmed by sequencing of the ITS regions of ribosomal DNA (3). In vitro susceptibility testing, 
using the CLSI M38-A method, revealed minimal inhibitory concentrations (MIC) of 8 mg/mL for 
voriconazole, 2 mg/mL for POS, 416 mg/mL for caspofungin, and 1 mg/ 
mL forAmB.  
 
Markers of inflammation rapidly declined after initiation of liposomal AmB and the patient’s clinical 
condition gradually improved. A follow-up CTscan of the chest on day 23 showed a cavitation of the 
lesionwith progressive signs of perifocal bleeding (Fig. 1b). Resection of the lesion was precluded by 
severe transfusion-refractory thrombocytopenia. POS (400 mg twice daily) was added to liposomal 
AmB on day 27 after admission.The serum trough level of POS one week later was 907 ng/mL. 
Despite a stable lesion in a second follow-up CT scan on day 48 after admission, the patient died on 






This case of breakthrough zygomycosis during POS prophylaxis highlights the need for continued 
awareness of invasive zygomycosis in patients receiving mold active antifungal prophylaxis. It 
documents the importance of a rapid diagnostic workup to facilitate active antifungal therapy and 
shows the limitations of current antifungal treatment regimens in persistently immunocompromised 
patients.  
 
Tissue levels of POSwere apparently not su⁄cient to prevent zygomycosis in this patient. Although 
target plasma levels have not yet been defined, levels determined in this patient suggest absorption 
despite intestinal GVHD. A dose-dependent antifungal e⁄ciency is suggested by 2 findings. First, 
higher POS serum levels were associated with higher response rates in the setting of salvage therapy 
for invasive aspergillosis (4). Second, pharmacokinetic data from the prophylaxis in GVHD trial 
showed a trend to lower plasma levels in 5 patients with breakthrough fungal infections compared with 
patients without fungal infections (median Caverage POS level of 611 vs. 922 ng/mL) (5).We determined 
trough levels, which are similar to average levels, as POS achieves a steady state after 7^10 days (5). 
 
Several reports suggest an association of long-term voriconazole administrationwith invasive 
zygomycosis, especially in recipients of allogeneic stem cell transplants (6^8). Although selective 
pressure appears to be aplausible explanation for this association, recent data from a mice model of 
Rhizopus oryzae infection suggest that pre-exposure to voriconazole may enhance the virulence of 
zygomycetes (9).  
 
Rapid initiation of in vitro active antifungals is of paramount importance in patients with zygomycosis. 
In an analysis of 70 patients with hematologic malignancies and zygomycosis, start of AmB treatment 
beyond day 6 after the onset of symptoms was associated with a poor outcome 
(10). In the case presented here, caspofungin was given because of pre-existing renal insu⁄ciency and 
suspected invasive aspergillosis due to malabsorption of POS. Antifungal therapy with caspofungin 
alone is inactive in zygomycosis and should not be used in patients with suspected mold infections 
during POS prophylaxis unless zygomycosis is ruled out.  
 
The in vitro activity of POS varies for different zygomycetes. Because interpretive breakpoints for 
susceptibility testing of POS are missing, approved breakpoints for fluconazole and voriconazole 
testing against Candida species have been taken as surrogate markers (11).Therefore, POS MIC 
have to be interpreted with caution. A mouse model suggests that, in contrast to other zygomycetes, 
higher doses of POS might be needed to treat infections due to R. microsporus (12).  
 
Optimal outcome of zygomycosis requires the reversal of underlying conditions, early antifungal 
therapy with highdose liposomal AmB, and surgical resection of involved tissue. In our patient, the 
  
underlying condition could not be reversed, surgery was not possible owing to transfusion-resistant 
thrombocytopenia, and preexisting renal insufficiency precluded high-dose AmB. Therefore, we used 
antifungal combination therapy when pulmonary lesions did not improve on AmB therapy on follow-up 
CT scans. The combination of AmB and POS is supported by a synergistic effect on hyphae of 
zygomycetes in vitro (13), in an animal model (14), and previous anecdotal experience in our center 
(15).  
 
Taken together, the reasons for treatment failure in this patientmight be insu⁄cient tissue levels of POS 
in necrotic lung tissue that could not be resected by surgery in combination with a state of severe and 
irreversible immunosuppression. Newer antifungal treatment approaches, such as chelation therapy 
that is currently under clinical investigation (16), are needed for the treatment of zygomycosis in 
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Figure 1 (a) Computed tomography (CT) of the chest on admission showing a mass lesion in the right 
upper lobe. (b) Follow-up CT on day 23 showing cavitation of the lesion and signs suggestive of 
perifocal bleeding. 
 
 
 
  
